Page 5 - Shivam Tyagi

L&T Q1FY25 analysis: Analysts eye order execution post strong June quarter

Shares of Larsen and Toubro rose 2.46 per cent at Rs 3606.25 per share on the BSE in Thursday's intraday trade

Torrent Pharma tanks 4% post Q1FY25 results; analysts update target prices

Shares of Torrent Pharma slumped up to 4.26 per cent at Rs 646.70 per share on the BSE in Tuesday's intraday deals. This came despite the Indian drugmaker delivering a strong April-June quarter

Cipla Q1 Preview: Restructure in biz may dent sales; profits to rise 7%

Cipla is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year on year basis and net profits seeing a mid single digit growth

Budget 2024-24: Why India VIX surged up to 17% today; check reasons here

On Tuesday, the volatility indicator for Indian bourses, India VIX surged up to 17.52 per cent intraday. This came amidst heightened volatility witnessed after the Budget 2024 speech

Wipro fails to show revival signs; may underperform peers, say analysts

Shares of Wipro plunged up to 8.79 per cent at Rs 508.25 per share on the BSE in Monday's intraday trade

Infosys stock best IT bet post Q1, say analysts; target price increased

This came after Infosys trumped street estimates in its financial performance for the first quarter of financial year 2024-25 (Q1FY25) while also giving higher growth guidance than expected for FY25

Realty check: Avoid buying commercial real estate stocks, caution analysts

On the bourses, shares of Prestige Estates, Oberoi Realty, Brigade Enterprises, DLF, Embassy REIT, and Mindspace Business Parks REIT, have surged in the range of 11 to 214 per cent

Wipro Q1 preview: Cost control to aid profit; top brass attrition in focus

Wipro may see a revenues in the range of Rs 22,195 crore to Rs 22,409 crore for Q1, a fall 1-3 per cent year-on-year (YoY)

Bajaj Auto Q1FY25 results: Profit rises 19% YoY to Rs 1,988 cr; stock up 2%

Bajaj Auto Q1 results: The share price surged after Bajaj Auto reported a solid performance in the first quarter ending June 30, 2024 (Q1FY25)

Nomura ups target price for Fortis, sees 12% upside; reiterates 'Buy'

The global brokerage firm maintained its 'Buy' call for Fortis Healthcare with an updated twelve month forward target price of Rs 547, a 12 per cent upside to Monday's close

Q1 Preview: Infosys to lead IT-pack, may see profits rise up to 10% YoY

Infosys is expected to lead the tier 1 Indian IT universe with the strongest growth, led by ramp-ups of multiple mega-deals, and a low base effectively providing one per cent kicker to June 2024

Brokerages raise target price for HCLTech after solid Q1 performance

Shares of HCL Tech zoomed 4.83 per cent at Rs 1635.85 per share on the BSE in Monday's early morning trade. This came after the IT services major reported a 20.4 per cent year on year increase profits

TCS Q1 review: Analysts eye revival; cheap valuation to aid stock rally

TCS Q1 review: According to brokerages, the revenue led beat to estimates was broad based-with almost every vertical reporting sequential growth

Stocks to watch, July 12: TCS, M&M, Affle, Nazara Tech, ABFRL, Anand Rathi

Stocks to watch on July 12: TCS recorded net profit of Rs 12,040 crore, up 8.7 per cent year-on-year, dollar revenue up 2.7 per cent sequentially to $7.5 billion

Tata Elxsi falls 3% as analysts caution on high valuation, near term risks

According to analysts, Tata Elxsi's revenue growth was led by ramp-up of deals in the transportation vertical but was offset by softness in the media and communication

Ambuja Cements poised for highest volume growth: Nomura upgrades to 'Buy'

Japanese brokerage firm Nomura has upgraded India's second biggest cement company Ambuja Cements to Buy with a target price of Rs 780, an upside of 17 per cent

Stocks to watch, July 11: YES Bank, Glenmark Pharma, Nykaa, SBI, Tata Elxsi

Stocks to watch, July 11: Global rating agency Moody's has revised its outlook on Indian private sector lender Yes Bank from "stable" to "positive"

HCL Tech Q1 Preview: Weak deals, client spending to dent profits by 5-7%

According to analysts, HCL Tech is likely to report a revenue increase of 6-7 per cent year-on-year (Y-o-Y) between Rs 27,900 crore to Rs 28,034 crore

Emcure Pharma lists at 31% premium; should you buy, sell or hold the stock?

Emcure Pharmaceuticals listing today: According to analysts, Emcure Pharma is quoting at a reasonable valuation with a niche opportunity to invest in the gynaecology & HIV antivirals therapeutic areas

Stocks to watch, July 10: Angel One, Emcure Pharma, Mankind Pharma, M&M

Stocks to watch on July 10: Emcure Pharmaceuticals' shares are scheduled to make their debut on the stock exchanges on Wednesday